LPL Financial’s Akari Therapeutics AKTX Stock Holding History

LPL Financial’s Portfolio AKTX Stock Details AKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-168	Closed	-$22.9K	–	4691
2023 Q2	$22.9K	Hold	168	–	–	﹤0.01%	4505
2023 Q1	$24.4K	Hold	168	–	–	﹤0.01%	4388
2022 Q4	$63.2K	Buy	168 +14	+9%	+$5.79K	﹤0.01%	4238
2022 Q3	$77K	Buy	154 +50	+48%	+$41.2K	﹤0.01%	4159
2022 Q2	$83K	Buy	+104	New	+$92.2K	﹤0.01%	4159

Other funds holding AKTX

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

OFW

Omnia Family Wealth Aventura, Florida $373M AUM 25.3% 1-Year Est. Return

Cerity Partners New York $70.8B AUM 21.68% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Truvestments Capital Sarasota, Florida $554M AUM 32.49% 1-Year Est. Return

CPG

Cornerstone Planning Group Fairfield, New Jersey $749M AUM 17.97% 1-Year Est. Return

LPL Financial's AKTX Position: Q3 2023 in Review

LPL Financial sold out of Akari Therapeutics (AKTX) in Q3 2023, closing a stake of 168 shares — an estimated $22.9K sold.

LPL Financial first reported a position in AKTX in Q2 2022 and held it in 5 quarters. The position peaked at $83K in Q2 2022. 7 funds tracked by Wall St. Rank hold AKTX as of Q3 2023.

LPL Financial reported no remaining Akari Therapeutics position as of Q3 2023 after selling out during the quarter.
LPL Financial sold 168 Akari Therapeutics shares in Q3 2023, an estimated $22.9K.
LPL Financial first reported a position in Akari Therapeutics in Q2 2022 and held it in 5 quarters.
LPL Financial's Akari Therapeutics position peaked at $83K in Q2 2022.
7 funds tracked by Wall St. Rank held Akari Therapeutics as of Q3 2023.

Based on LPL Financial's 13F filing for Q3 2023, filed 13 Nov 2023.